Cingulate (CING) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 May, 2026Voting matters and shareholder proposals
Election of Jeff Hargroves as Class II director to serve until the 2029 annual meeting and until a successor is elected.
Ratification of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.
Approval of an amendment to the 2021 Omnibus Equity Incentive Plan to increase authorized shares by 625,000 to a total of 2,221,126 shares.
Approval to adjourn the Annual Meeting if necessary to permit further solicitation and voting of proxies.
Consideration of any other matters that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends a vote FOR all proposals and the director nominee listed.
Audit committee and external auditor matters
Proposal to ratify KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year.
Latest events from Cingulate
- Shareholders will vote on director election, auditor ratification, and expanding the equity incentive plan.CING
Proxy filing29 May 2026 - Board recommends approval of director election, auditor ratification, and equity plan amendment.CING
Proxy filing19 May 2026 - Q1 2026 net loss rose to $9.3M as cash climbed to $25.9M ahead of FDA review.CING
Q1 202614 May 2026 - CTX-1301 aims to disrupt the ADHD market with once-daily efficacy and strong clinical results.CING
Corporate presentation14 Apr 2026 - Advancing once-daily ADHD and anxiety drugs with $12M raised, but faces going concern risk.CING
Registration filing14 Apr 2026 - Shelf registration enables flexible securities issuance; auditor consent updated.CING
Registration filing23 Mar 2026 - Up to 3.5M shares may be sold to Lincoln Park for up to $25M to fund CNS drug development.CING
Registration filing20 Mar 2026 - Beneficial ownership table updated to include a 5% stockholder and clarify voting procedures.CING
Proxy Filing18 Mar 2026 - 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised.CING
Q4 202518 Mar 2026